Sai Life Sciences opens new Research & Technology Centre in Hyderabad
One of India's fastest growing CDMOs goes "beyond the norm" to reinvent itself as a new generation global CDMO.
Sai Life Sciences has inaugurated its new Research and Technology (R&T) Centre in Hyderabad, India.
The company claims the new R&T facility has several unique aspects such as intelligent and ergonomic lab design to enhance safety and productivity, advanced automation for seamless data capture during process development, lean & 5S approach to enhance productivity and collaborative workspaces for engendering innovation.
Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences said the company's philosophy behind building this new facility was to "go beyond what the norm is in India and to create what our global innovator partners expect in their inhouse capabilities".
The new 83,000-sq. ft (7700 m2) facility houses state-of-the-art research capabilities and advanced technology platforms, augmenting the company's capabilities in providing superior scientific solutions to its pharma and biotech innovator customers globally. It has 24 chemistry labs with 250 fume hoods, analytical labs, fully equipped technology suite and a dedicated process safety lab.
Sai Life Sciences began a process of organizational transformation in 2019 reinventing itself as a new generation global CDMO. Through this initiative, named Sai Nxt, the company is investing more than $150 million (> INR 1000 Cr) to expand and upgrade its R&D and manufacturing facilities, induct top global scientific and leadership talent, strengthen automation and data systems, and raise the bar for safety, quality and customer focus.
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc... -
News Key takeaways from Saudi Arabia's National Biotechnology Strategy
In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance